Inicio › Cáncer de próstata › Connecticut
Ensayos clínicos de Cáncer de próstata en Connecticut
29 estudios sobre Cáncer de próstata buscan participantes en Connecticut.
Ciudades en Connecticut
Texto oficial del estudio (inglés)
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- y 2 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT04557449A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Yale Cancer Center, New Haven
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 5 nov 2026 · NCT07567846Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Stamford Hospital/Bennett Cancer Center, Stamford
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06632977Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Yale University, New Haven
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT06800313A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Yale Cancer Center, New Haven
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT05800665A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
- Hartford Healthcare Alliance (Data collection only), Hartford
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 30 oct 2026 · NCT05751434A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0050), New Haven
- Veterans Affairs Connecticut Healthcare System ( Site 0062), West Haven
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 30 oct 2026 · NCT06925737Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Yale New Haven Hospital, New Haven
ReclutandoFase 1
Edades de 18 a 100 · Hombres · Actualizado el 29 oct 2026 · NCT05519449A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT06136650A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hartford HealthCare Cancer Institute at Hartford Hospital, Hartford
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 20 oct 2026 · NCT07213674Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- Yale University, New Haven
- Stamford Hospital/Bennett Cancer Center, Stamford
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 8 oct 2026 · NCT03678025FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Yale University School of Medicine, New Haven
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 oct 2026 · NCT05919264A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- GSK Investigational Site, New Haven
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 5 oct 2026 · NCT06990880The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Hartford Hospital, Hartford
ReclutandoFase 2/3
Edades de 18 a 100 · Hombres · Actualizado el 22 sept 2026 · NCT06780670High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 17 sept 2026 · NCT05011383The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
- Yale Cancer Center, New Haven
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 14 sept 2026 · NCT06111781A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth
- Wren Laboratories, Branford
ReclutandoEstudio observacional
Edades de 45 a 80 · Hombres · Actualizado el 21 ago 2026 · NCT07454603A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- New Haven Hospital - Yale Cancer Center, New Haven
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 17 ago 2026 · NCT06842498Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 14 jul 2026 · NCT06592924Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- Yale University (Data Collection Only), New Haven
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 25 jun 2026 · NCT06457919Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Hartford Hospital, Hartford
ReclutandoFase 4
Edades de 18 a 100 · Hombres · Actualizado el 4 jun 2026 · NCT05803941International Registry for Men With Advanced Prostate Cancer (IRONMAN)
- Yale University, New Haven
ReclutandoEstudio observacional
Edades de 21 en adelante · Hombres · Actualizado el 22 may 2026 · NCT03151629A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Yale University, Yale Cancer Center, New Haven
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 mar 2026 · NCT06395519Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- y 11 más
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 29 ene 2026 · NCT05806515SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hartford
- Massive Bio SYNERGY-AI site, Norwalk
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.